INKT (MiNK Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


INKT MiNK Therapeutics Inc INKT
34 GF Score
Price $11.46
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics ROE % Adjusted to Book Value?

MiNK Therapeutics INKT -3.29% 34 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

MiNK Therapeutics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. MiNK Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was N/A. MiNK Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

MiNK Therapeutics ROE % Adjusted to Book Value Related Terms

MiNK Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics ROE % Adjusted to Book Value Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

INKT vs BOLD, FLNA, DWTX: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, MiNK Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiNK Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's ROE % Adjusted to Book Value falls into.


INKT
34GF Score
MiNK Therapeutics Inc INKT
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics ROE % Adjusted to Book Value Calculation

MiNK Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

MiNK Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
MiNK Therapeutics (INKT) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MiNK Therapeutics and its competitors.
Is MiNK Therapeutics' ROE % Adjusted to Book Value too high?
MiNK Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' ROE % Adjusted to Book Value compare to BOLD and FLNA?
MiNK Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score

Get the complete analysis for INKT

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.46
Price